Insurance Coverage Policies for Personalized Medicine

Adoption of personalized medicine in practice has been slow, in part due to the lack of evidence of clinical benefit provided by these technologies. Coverage by insurers is a critical step in achieving widespread adoption of personalized medicine. Insurers consider a variety of factors when formulating medical coverage policies for personalized medicine, including the overall strength of evidence for a test, availability of clinical guidelines and health technology assessments by independent organizations. In this study, we reviewed coverage policies of the largest U.S. insurers for genomic (disease-related) and pharmacogenetic (PGx) tests to determine the extent that these tests were covered and the evidence basis for the coverage decisions. We identified 41 coverage policies for 49 unique testing: 22 tests for disease diagnosis, prognosis and risk and 27 PGx tests. Fifty percent (or less) of the tests reviewed were covered by insurers. Lack of evidence of clinical utility appears to be a major factor in decisions of non-coverage. The inclusion of PGx information in drug package inserts appears to be a common theme of PGx tests that are covered. This analysis highlights the variability of coverage determinations and factors considered, suggesting that the adoption of personal medicine will affected by numerous factors, but will continue to be slowed due to lack of demonstrated clinical benefit.

[1]  T. Klingler,et al.  Clinical implications and longitudinal alteration of peripheral blood transcriptional signals indicative of future cardiac allograft rejection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  I. Bruce,et al.  Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription , 2007, Journal of clinical pharmacy and therapeutics.

[3]  Personalized medicine and disruptive innovation: Implications for technology assessment , 2009, Genetics in Medicine.

[4]  B. J. Barratt,et al.  Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial , 2010, The Lancet.

[5]  Robert H. Christenson,et al.  The National Academy of Clinical Biochemistry , 2007 .

[6]  N. Smedira,et al.  Transplant vasculopathy is associated with increased AlloMap gene expression score. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  J. Ormiston,et al.  The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. , 2008, JACC. Cardiovascular interventions.

[8]  M. Wynia,et al.  U.S. physician knowledge of the FDA‐approved indications and evidence base for commonly prescribed drugs: results of a national survey , 2009, Pharmacoepidemiology and drug safety.

[9]  K. Phillips,et al.  Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. , 2010, Journal of oncology practice.

[10]  Personalized Medicine: Trends and Prospects for the New Science of Genetic Testing and Molecular Diagnostics-Working Paper 7 , 2012 .

[11]  M. Pencina,et al.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. , 2011, JAMA.

[12]  Julianne M. O’Daniel,et al.  Public perspectives about pharmacogenetic testing and managing ancillary findings. , 2012, Genetic testing and molecular biomarkers.

[13]  Peter J Neumann,et al.  Personalized medicine: factors influencing reimbursement. , 2010, Health policy.

[14]  Joshua P Cohen,et al.  Clinical and economic challenges facing pharmacogenomics , 2012, The Pharmacogenomics Journal.

[15]  B. Giusti,et al.  Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis , 2011, The Pharmacogenomics Journal.

[16]  L. Roberts,et al.  Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry. , 2010, The Journal of clinical psychiatry.

[17]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[18]  S. Tunis,et al.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'. , 2006, Health affairs.

[19]  Paul Nightingale,et al.  Putting pharmacogenetics into practice , 2006, Nature Biotechnology.

[20]  F. Frueh,et al.  Payer perspectives on pharmacogenomics testing and drug development. , 2009, Pharmacogenomics.

[21]  U. Heine,et al.  HLA-B*5701 clinical testing: early experience in the United States , 2007, Pharmacogenetics and genomics.

[22]  Shashi Amur,et al.  Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use , 2008, Pharmacotherapy.

[23]  Deepak L. Bhatt,et al.  Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. , 2010, The New England journal of medicine.

[24]  S. Scott,et al.  Personalizing medicine with clinical pharmacogenetics , 2011, Genetics in Medicine.

[25]  M. Lai-Goldman,et al.  Application of a pharmacogenetic test adoption model to six oncology biomarkers. , 2010, Personalized medicine.

[26]  Muin J. Khoury,et al.  The evidence dilemma in genomic medicine. , 2008, Health affairs.

[27]  Daniel Bernstein,et al.  Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  F. Frueh.  Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. , 2010, Pharmacogenomics.

[29]  T. Lash,et al.  Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Smedira,et al.  Post‐transplant ischemic injury is associated with up‐regulated AlloMap gene expression , 2007, Clinical transplantation.

[31]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[32]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[33]  Dear Governor Lehman.  THE WHITE HOUSE , 1974 .

[34]  M. Linder,et al.  Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice , 2005 .

[35]  M. Khoury,et al.  Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies , 2012, Genetics in Medicine.

[36]  J. Ashby.  References and Notes , 1999 .

[37]  K. Phillips,et al.  Health technology assessment and private payers' coverage of personalized medicine. , 2011, Journal of oncology practice.

[38]  P. Deverka.  Pharmacogenomics, Evidence, and the Role of Payers , 2009, Public Health Genomics.

[39]  W. Newman,et al.  Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. , 2010, Genetic testing and molecular biomarkers.

[40]  I Zineh,et al.  Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs , 2004, The Pharmacogenomics Journal.

[41]  S. Kaul,et al.  ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association , 2010, Circulation.

[42]  G. Montalescot,et al.  Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. , 2010, Journal of the American College of Cardiology.

[43]  Geoffrey S Ginsburg,et al.  The long and winding road to warfarin pharmacogenetic testing. , 2010, Journal of the American College of Cardiology.